{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for sulfacetamide in Related Substance Name (approximate match)
Showing 1 - 8 of 8 results
Status:
US Approved Rx
(2016)
Source:
NDA207154
(2016)
Source URL:
First approved in 1955
Class (Stereo):
CHEMICAL (ACHIRAL)
Dapsone was synthesized in 1908 by Fromm and Wittmann. The drug was approved by FDA for the treatment of such conditions as acne vulgaris, leprosy and dermatitis herpetiformis, also the drug is used off-label for many skin diseases. Although the exact mechanism of dapsone action is unknown, it is speculated that it acts as both anti-inflammatory and antimicrobial agent. It was demonstrated that dapsone suppresses ROS generation, inhibits neutrophil myeloperoxidase and eosinophil peroxidase and also inhibits bacterial dihydropteroate synthase.
Status:
US Approved Rx
(1994)
Source:
ANDA040066
(1994)
Source URL:
First approved in 1941
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Sulfacetamide is a synthetic sulfonamide antibiotic, which exerts its effect through inhibition of bacterial dihydrofolate synthetase, an enzyme responsible for the conversion of p-aminobenzoic acid into folic acid in bacterias. The topical formulation of the drug is prescribed for the treatment of acne vulgaris and the ophtalmic formulation is used in patients with eye infections.
Status:
US Approved Rx
(1994)
Source:
ANDA040066
(1994)
Source URL:
First approved in 1941
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Sulfacetamide is a synthetic sulfonamide antibiotic, which exerts its effect through inhibition of bacterial dihydrofolate synthetase, an enzyme responsible for the conversion of p-aminobenzoic acid into folic acid in bacterias. The topical formulation of the drug is prescribed for the treatment of acne vulgaris and the ophtalmic formulation is used in patients with eye infections.
Status:
US Approved Rx
(1994)
Source:
ANDA040066
(1994)
Source URL:
First approved in 1941
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Sulfacetamide is a synthetic sulfonamide antibiotic, which exerts its effect through inhibition of bacterial dihydrofolate synthetase, an enzyme responsible for the conversion of p-aminobenzoic acid into folic acid in bacterias. The topical formulation of the drug is prescribed for the treatment of acne vulgaris and the ophtalmic formulation is used in patients with eye infections.
Status:
US Previously Marketed
Source:
LANTRISUL by LANNETT
(1978)
Source URL:
First approved in 1947
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Sulfamethazine is a sulfonamide used to treat a variety of bacterial diseases in animals. It inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for binding to dihydropteroate synthetase (dihydrofolate synthetase).
Status:
US Previously Marketed
Source:
AVC by MYLAN SPECIALITY LP
(1965)
Source URL:
First marketed in 1936
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Sulfanilamide is an anibiotic drug, which has been used for decades for the treatment of vulvovaginal candidiasis. The drug blocks folic acid synthesis in bacterias by inhibitin the enzyme dihydropteroate synthase.
